The Q3 preliminary results show accelerating revenue growth and improving cash burn efficiency, with revenue exceeding cash burn for the first time. The full Q3 earnings call on November 9, 2026 will provide complete financials and any updates to guidance. Key catalysts to watch include the Contrast PMR study FDA submission by end of 2026 and continued commercial traction in hospital, office, and international markets.
Price Chart
Executive Summary
Hyperfine reported record preliminary Q3 2026 revenue of approximately $6.0M, up 53% sequentially from Q2 2026, and reaffirmed full-year 2026 revenue guidance of $20-22M. Revenue exceeded net cash burn for the first time, marking an operational inflection point. The company also highlighted strong commercial momentum across hospital, office, and international verticals.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue of approximately $6.0M, up 53% sequentially from Q2 2026
- Preliminary Q3 2026 net cash burn of approximately $5.6M, down 29% sequentially from Q2 2026
- Revenue exceeded net cash burn for the first time in Q3 2026
- Full-year 2026 revenue guidance reaffirmed at $20-22M (55% YoY growth at midpoint)
- Full-year 2026 net cash burn guidance reaffirmed at $26-28M (10% decline at midpoint)
- Preliminary cash and cash equivalents of approximately $37.9M as of September 30, 2026
- Nine-month 2026 preliminary revenue of approximately $13.8M, up 66% YoY
- Nine-month 2026 preliminary net cash burn of approximately $22.2M, an 8% improvement YoY
- No financing proceeds raised in Q3 2026
- Installed base of over 225 Swoop systems globally
- Contrast PMR study enrollment complete; FDA submission targeted by end of 2026
Financial Impact
Record preliminary Q3 revenue of ~$6.0M (+53% QoQ) and first-time revenue > cash burn; FY2026 guidance reaffirmed at $20-22M revenue and $26-28M cash burn
Risk Factors
- Preliminary results are unaudited and subject to change upon completion of quarter-end closing procedures
- Company is still pre-profitability with accumulated deficit of $338.6M as of March 31, 2026
- Dependence on successful commercialization of Model 2 Swoop system and Optive AI software
- Regulatory clearance for contrast imaging indication not yet obtained
- Competition from conventional MRI and other portable imaging technologies
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-417437 |
| Document: d142207d8k.htm | 0001193125-26-417437 |
| Document: d142207dex991.htm | 0001193125-26-417437 |
| Document: 0001193125-26-417437-index-headers.html | 0001193125-26-417437 |
| Document: 0001193125-26-417437-index.html | 0001193125-26-417437 |
| Document: 0001193125-26-417437.txt | 0001193125-26-417437 |
| 8-K Data (Synthetic) | 0001193125-26-417437 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 8-K | $0.9401 $0.7801 | ▼ −17.02% | ▼ −16.74% | $0.7500 (−20.22%) |
May 22, 2026 22w ago | EFFECT | $1.49 $1.52 | ▲ +2.01% | ▲ +0.36% | $0.7500 (−49.66%) |
May 12, 2026 24w ago | S-3 | $1.59 $1.41 | ▼ −11.32% | ▼ −10.16% | $0.7500 (−52.83%) |
Apr 8, 2026 28w ago | DEFA14A | $1.21 $1.33 | ▲ +9.92% | ▲ +6.73% | $0.7500 (−38.02%) |
Mar 23, 2026 31w ago | Insider Cluster | $1.21 $1.03 | ▲ +14.88% | ▲ +11.31% | $0.7500 (+38.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers